Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

The user is discussing hair regrowth after 7 months of using topical minoxidil and RU58841, with some microneedling. They are hesitant to switch to finasteride or dutasteride and are seeking input on whether there is new growth or just more miniaturization.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.

An 18-year-old is using a high-dose hair loss treatment regimen including finasteride, minoxidil, dutasteride, and plans to add RU58841 and bimatoprost, despite warnings from others about the risks. The user is determined to reverse hair loss but acknowledges the potential dangers and does not recommend others follow their approach.

A 113 year old man who has more hair than most people, and the conversation is discussing potential genetic factors that may be responsible for this. Possible treatments such as dermarolling and minoxidil, finasteride, and RU58841 are mentioned.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

A 7-month update of hair regrowth achieved by using daily topical finasteride and minoxidil, combined with weekly microneedling. It is also noted that the results are different for females.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Akkermansia bacteria can improve hair growth inhibited by testosterone, and metformin may increase Akkermansia, which could help with hair loss related to aging, insulin resistance, and inflammation.

The conversation is about a failed hair loss theory involving sulforaphane. The person who proposed it is now bald and focusing on fitness.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.

The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

Topical pirfenidone is highlighted as an effective anti-inflammatory and anti-fibrotic treatment for hair loss, particularly in addressing perifollicular fibrosis, which may enhance the effectiveness of standard treatments like finasteride and minoxidil. The user also uses calcipotriol, MCT oil, ciclopirox shampoo, and benzoyl peroxide shampoo as part of their regimen.

A 49-year-old is documenting their hair regrowth journey using tretinoin cream, minoxidil foam, and finasteride. They report thicker hair and improved confidence, though progress feels slow and mentally challenging.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

Minoxidil's effectiveness varies due to genetic differences in the SULT1A1 enzyme, affecting how well it converts to its active form, minoxidil sulfate. Hyper-responders may experience rapid hair growth and increased side effects, such as pericardial effusion, even at low doses.

A 30-year-old shared their 7-month hair regrowth progress using topical minoxidil twice daily, 1 mg finasteride daily, and weekly microneedling. Users discussed the effectiveness of these treatments and suggested adding retinol for better results.

Insulin resistance may increase DHT production, contributing to hair loss, and addressing it through diet, nutrients, and natural DHT blockers like saw palmetto and pumpkin seed oil could help reverse hair loss. Some users prefer medications like finasteride for more effective results.